Accessibility Menu
 
Aprea Therapeutics logo

Aprea Therapeutics

(NASDAQ) APRE

Current Price$1.01
Market Cap$11.45M
Since IPO (2022)-93%
5 Year-99%
1 Year-33%
1 Month+37%

Aprea Therapeutics Financials at a Glance

Market Cap

$11.45M

Revenue (TTM)

$285.76K

Net Income (TTM)

$12.60M

EPS (TTM)

$-1.97

P/E Ratio

-0.51

Dividend

$0.00

Beta (Volatility)

-0.82 (Low)

Price

$1.01

Volume

25,953

Open

$0.95

Previous Close

$1.01

Daily Range

$0.95 - $1.12

52-Week Range

$0.55 - $2.22

APRE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aprea Therapeutics

Industry

Biotechnology

Employees

8

CEO

Oren Gilad, PhD

Headquarters

Boston, MA 02116, US

APRE Financials

Key Financial Metrics (TTM)

Gross Margin

92%

Operating Margin

-46%

Net Income Margin

-44%

Return on Equity

-75%

Return on Capital

-1%

Return on Assets

-79%

Earnings Yield

-1.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.45M

Shares Outstanding

11.45M

Volume

25.95K

Short Interest

0.00%

Avg. Volume

2.35M

Financials (TTM)

Gross Profit

$264.04K

Operating Income

$13.23M

EBITDA

$13.23M

Operating Cash Flow

$12.89M

Capital Expenditure

$0.00

Free Cash Flow

$12.89M

Cash & ST Invst.

$14.60M

Total Debt

$0.00

Aprea Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$3.34K

-98.4%

Gross Profit

$4.38M

+303.5%

Gross Margin

1313.25%

N/A

Market Cap

$11.45M

N/A

Market Cap/Employee

$1.43M

N/A

Employees

8

N/A

Net Income

$2.46M

+15.2%

EBITDA

$2.64M

+18.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$14.60M

-36.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-79.08%

N/A

Return on Invested Capital

-1.00%

N/A

Free Cash Flow

$3.07M

+12.6%

Operating Cash Flow

$3.07M

+12.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APVOAptevo Therapeutics Inc.
$5.28-5.88%
KPRXKiora Pharmaceuticals, Inc.
$2.52+1.20%
RNAZTransCode Therapeutics, Inc.
$8.80+1.15%
BCDABioCardia, Inc.
$1.18-0.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
EFOIEnergy Focus
$6.49+2.11%
NVDANvidia
$201.68+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.90+0.06%
NFLXNetflix
$97.31-0.10%

Questions About APRE

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.